Regulatory – Page 6 – Alligator Bioscience

2023-05-11

Regulatory

Alligator Bioscience and Orion Corporation announce exercise of development option under their 2021 Immuno-oncology Research Collaboration and License Agreement

Orion selects lead antibodies from the first discovery program Collaboration aims to discover and develop new bispecific antibody cancer the ...

2023-05-092023-05-10

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2023-04-262023-04-26

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2023-04-26

Regulatory

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...

2023-04-24

Regulatory

Today, on 24 April 2023, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows ...

2023-03-24

Regulatory

Lund, Sweden, March 24, 2023 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2022 has been publi ...

2023-03-222023-03-29

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2023-01-02

Regulatory

52% Objective Response Rate in pre-planned interim efficacy analysis of mitazalimab combined with mFOLFIRINOX in 1st line metastatic pancrea ...

2023-01-02

Regulatory

The second project aims to develop a bispecific antibody with potential applications in solid tumors Alligator and Orion each to provide val ...